Penserra Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Penserra Capital Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,652	Closed	-$122K	–	1275
2022 Q2	$122K	Buy	4,652 +1,593	+52%	+$45.2K	﹤0.01%	743
2022 Q1	$107K	Sell	3,059 -580	-16%	-$16.9K	﹤0.01%	827
2021 Q4	$117K	Sell	3,639 -680	-16%	-$24K	﹤0.01%	804
2021 Q3	$127K	Sell	4,319 -4,425	-51%	-$124K	﹤0.01%	718
2021 Q2	$224K	Sell	8,744 -6,018	-41%	-$86.1K	﹤0.01%	622
2021 Q1	$202K	Sell	14,762 -6,939	-32%	-$102K	﹤0.01%	578
2020 Q4	$359K	Buy	+21,701	New	+$282K	0.01%	415

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Penserra Capital Management's CERE Position: Q3 2022 in Review

Penserra Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2022, closing a stake of 4,652 shares — an estimated $122K sold.

Penserra Capital Management first reported a position in CERE in Q4 2020 and held it in 7 quarters. The position peaked at $359K in Q4 2020. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.

Penserra Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Penserra Capital Management sold 4,652 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $122K.
Penserra Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Penserra Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $359K in Q4 2020.
114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.